Generation and discovery of high affinity antibodies
May 2, 2022
Speaker: Li Hui, MD, Ph.D. Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Introduced Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat. Provided proof-of-concept data supporting the robust capabilities of the platform to identify high-quality antibodies with therapeutic potential.
Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice
March 18, 2022
Speaker: Yi (Benny) Yang, Ph.D. Chief Scientific Officer, Biocytogen Beijing Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets Analyzed the design, screening and drug discovery of bispecific antibodies and bispecific-ADC drugs in two case studies
AET Europe 2021: Powerful Engine for Therapeutic Antibody Discovery – RenMab/RenLite Immunoglobulin Humanized Mouse Platform
June 17, 2021
Learn more about Biocytogen’s established first and second generation of immunoglobulin humanized mouse platforms: RenMab and RenLite.
FcRn Therapies 2021 Conference: Humanized Mouse Models to Assess the In Vivo Efficacy of Antibody Therapeutics
March 25, 2021
Learn about the powerful models of Humanized mouse in IL4/IL4RA and IL-17 mice in various in-vivo settings
AET Europe 2020: Advancing Therapeutic Antibody discovery using RenMab/RenLite/RenMab KO immunoglobulin humanized mouse platforms
January 7, 2021
To meet the expanding needs of the therapeutic antibody market, Biocytogen established first and second generation of immunoglobulin humanized mouse platforms: RenMab, RenMab KO and RenLite.
In Vivo vs. In Vitro Therapeutic Antibody Discovery
October 2, 2020
in vivo antibody discovery using transgenic/humanized mice is of rising importance for the antibody community as it offers a multitude of benefits over in vitro methods
Antibody Discovery Platforms and RenMab Mouse
October 2, 2020
The humanized mouse model is the preferred means to produce fully-human antibodies for therapeutics discovery
